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. Approximately 90 million Europeans are affected by allergic respiratory diseases.
• In Germany, 25% of the adult population and 21% of children suffer from allergic rhinoconjunctivitis (AR) 2 .
• According to the ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines, 10-40% of patients suffer from co-existing allergic asthma 3 .
• Treatment of AR mainly consists of symptom control achieved by allergen avoidance or use of symptomatic drug treatment (SDT). In poorly controlled AR patients in Germany, causal treatments such as allergen immunotherapy (AIT) may be required 4, 5 .
A health economic assessment, reflective of German clinical practice, was conducted to determine the relative impact on clinical effects, expressed as SFD, and healthcare costs when treating patients with moderate-to-severe grass polleninduced allergic rhinoconjunctivitis with Oralair® or Grazax®. o The annual probability of developing asthma with SLIT treatment of 0.23% was based on a number of published sources 11, 12, 13 . Patients with asthma have a slightly higher annual probability to die relative to the general population (e.g. 0.046% vs. 0.069% for a 29-year-old patient) 14 .
• Annual drug costs per season are €700 for Oralair and €1,347 for Grazax (assuming a fully adherent patient). These and other resource use and cost data are based on drug product information combined with rules of the German remuneration system.
• Due to the fact that treatment with Oralair • Table 1 shows an overview of the SFD data extracted from the clinical trials, and the results of the indirect treatment comparison.
• The proportion of SFDs is multiplied with the assumed length of a pollen season in order to obtain the absolute number of SFDs per season. Subsequently, these values were summed over time to obtain the total number of SFDs over the complete model time span.
Health economic model, input parameters and assumptions
• An existing health economic model insurants; disease-related benefits covered by SHI are reflected as well as co-payments by insurants.
• A number of other clinical inputs were included in the model, but it is worth noting that these inputs were only used for purposes of estimation of the total costs for each strategy. These model inputs did not differ between the two alternatives:
• In Table 2 , the cost breakdown indicates that the difference in costs after 9 years is mostly driven by the difference in immunotherapy costs in Germany; 3 years of treatment with Oralair • The base case analysis determines the total costs and total SFDs, and the incremental results are calculated when Oralair ® is compared to Grazax ® .
• Sensitivity analyses were conducted, taking into account the variability of each model parameter (all parameters are included, except drug costs as these are fixed), in order to determine the 95% confidence intervals around the incremental SFD results and difference in costs.
• Since head-to-head comparative data is not currently available, the relative efficacy of SFD was estimated by applying an indirect comparison of available published clinical trials.
• The observed SFDs one year post-treatment at year 4 were assumed to remain constant until 9 years.
• The impact of adverse events was not considered in the analysis.
The results of the economic analysis suggest that Oralair • The (long-term) clinical effects of these two therapies during and post-treatment are most widely evaluated compared to other immunotherapy agents 6, 7 • Apart from their impact on symptom scores, both therapies also reported data on another important clinical outcome measure: symptom-free days (SFD).
o By definition, a SFD corresponds to the proportion of days with total absence of rhinoconjunctivitis symptoms in the absence of rescue medication intake
• This may facilitate healthcare decision-making, as providers and decision-makers are required to assess the health benefits and cost consequences associated with an intervention and, subsequently, make decisions regarding its value for money. 
RESULTS
In Table 2 , the cost breakdown indicates that the difference in costs after 9 years is mostly driven by the difference in immunotherapy costs in Germany; 3 years of treatment with Oralair Results of the uncertainty analyses further indicate that, besides drug costs, incremental costs are mostly driven by the length of the pollen season. 
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